Color-enhanced staphylococcus bacteria (NIH)
Morphotek Inc., a developer of protein and antibody products in Exton, Pennsylvania, said it received a $2.5 million contract from the U.S. Department of Defense (DoD) to fund further development of the company’s monoclonal antibody therapies against disease-causing staphylococcal strains and toxins.
In February 2008, Morphotek received funding to support initial development of these therapies. This new award will continue the research and development of antibodies directly targeting disease-causing staphylococcal toxins and strains for the development of treatments. The company says its technology produces monoclonal antibodies that bind and neutralize the toxic effects of microbial pathogens in an animal model to generate therapeutic antibodies to treat diseases.
The contract was awarded by the United States Army Medical Research Institute of Infectious Diseases at Fort Detrick, Maryland. The institute conducts and funds research on biological threats resulting in medical solutions such as vaccines, drugs and diagnostics to protect military personnel.
RSS - Posts
You must be logged in to post a comment.